$NKTR

A federal jury ruled that Eli Lilly & Co. breached the implied covenant of good faith and fair dealing with Nektar Therapeutics, awarding Nektar $90 million in damages. The jury rejected Nektar's claim that Lilly breached the license agreement's commercially reasonable efforts (CRE) obligation. Lilly plans to appeal, arguing no liability should have been imposed. The case highlights risks in biopharma licensing agreements.

Nektar Therapeutics (NKTR) won a $115 million lawsuit against Eli Lilly (LLY), resolving a multi-year overhang. The verdict, including interest, amounts to ~5% of NKTR's market cap. Despite the win, NKTR's stock fell over $200 million in market cap due to market volatility and rising yields. Cedar Grove Capital Management views this as a net positive for NKTR, removing a long-standing uncertainty.

Nektar Therapeutics (NKTR) stock fell 27.85% in a week and 41.26% in a month, closing at $43.58 on October 2, 2026. Analysts cite clinical uncertainty, target price cuts, and dilution concerns. H.C. Wainwright maintains a Buy rating with a $185 target, while Citi sees a buying opportunity. The company reported a narrower-than-expected loss but missed revenue estimates. Cash and debt figures show discrepancies. The stock's outlook is highly binary, dependent on Phase 3 trial results.

H.C. Wainwright reiterated a Buy rating and $185 price target on Nektar Therapeutics (NKTR) after positive alopecia data. NKTR shares fell 22.4% on Oct 1, despite analysts' bullish consensus. NKTR reported a smaller-than-expected Q2 2026 loss but missed revenue expectations. NKTR won a $90M verdict against Eli Lilly.

HC Wainwright & Co. maintained a Buy rating on Nektar Therapeutics with a $185 price target, suggesting a 293.7% upside from the Oct 1 close of $46.99. The firm cited strong Phase 2b data for rezpeg and an undervalued stock as reasons for the recommendation.

Nektar Therapeutics (NKTR) shares fell 21% after reporting modest new response rates for its experimental skin drug, rezpegaldesleukin, in alopecia and eczema studies. Despite this, analysts at William Blair and Jefferies maintained bullish ratings, citing the drug's durability advantage. The company also faces an ongoing legal dispute with Eli Lilly.

Nektar Therapeutics (NKTR) shares fell despite positive trial data for its alopecia drug, rezpegaldesleukin. The study showed 29% (low dose) and 31% (high dose) of patients benefited for six months without treatment. The drug is also being tested for eczema and diabetes.

Nektar reported positive Phase 2b results for rezpegaldesleukin in alopecia areata and atopic dermatitis, showing durable responses. 31% of patients achieved SALT ≤20 after 52 weeks, with 63% maintaining it 6 months off treatment. Phase 3 trials, ZENITH AA and ZENITH AD, are planned to start in early 2027. According to the company, the data supports the drug's potential.

Nektar Therapeutics (NKTR) presented long-term data on rezpegaldesleukin at EADV 2026, showing durable hair regrowth in alopecia areata patients and sustained improvements in atopic dermatitis. Key findings include 75% maintaining SALT Score ≤20 after 4 months off-treatment and 19% achieving SALT Score ≤10 after 6 months. Phase 3 studies are planned for both indications, with ZENITH AA to start in early 2027. The company will host an investor call on Oct. 1, 2026.

Nektar Therapeutics (NKTR) presented data at EADV Congress 2026 showing early molecular responses to rezpegaldesleukin in atopic dermatitis patients. The drug demonstrated significant biomarker changes by Week 2, correlating with clinical improvement. The Phase 2b REZOLVE-AD study involved 100 patients, with a 64% reduction in EASI score at Week 16 in the molecular cohort. Rezpegaldesleukin targets the IL-2 receptor to stimulate regulatory T cells, aiming to restore immune balance.